Asset overview
Program snapshot
Target: EGFRvIII
Cell type: NK_CELL
Indications: Glioblastoma, High-grade Glioma, Malignant Glioma, Recurrent Glioblastoma, Recurrent High-grade Glioma
Sponsor: Beijing Biotech
Institution: Beijing Biotech
Car Nk
Dual-target CAR-NK cells
Dual-target CAR-NK cells is flagged as a partnering watch because it has an active early-phase oncology cell-therapy trial at Beijing Biotech, with a probable patent signal linked through target_match, modality_match. Manual review is still required.
Clinical evidence
Trial footprint
Phase: Phase1
Status: Recruiting
Trial count: 2
Active trials: 0
First posted: March 18, 2026
Last updated: March 18, 2026
Signal summary
IP and BD posture
IP signal: Probable
BD label: Partnering Watch
Confidence: High
Manual review required: Yes
Scores
Deterministic scoring
Clinical translation4
IP linkage4
Licensing clarity2
Strategic interest5
Source
Public trial record
Review the underlying ClinicalTrials.gov record and treat Treelip output as a prioritization layer, not a final diligence conclusion.
NCT IDs: NCT07480941, NCT07551336